What is the expected growth rate of the Radiation Toxicity market?

The market is projected to grow at a CAGR of 5.5% from 2026 to 2033, fueled by advancements in radioprotective drugs and diagnostic tools.

What are the key drivers of the Radiation Toxicity market?

Key drivers include increased nuclear power plant operations, rising cancer treatment prevalence, and growing radiological terrorism concerns.

What challenges hinder the Radiation Toxicity market growth?

High R&D costs, limited treatment options, and stringent regulatory approvals pose significant barriers to market expansion.

Which regions are leading the Radiation Toxicity market?

North America leads the market, followed by Europe, due to advanced healthcare infrastructure and high radiation exposure awareness.

Who are the top companies in the Radiation Toxicity market?

Leading players include Fresenius Kabi AG, ICN Pharmaceuticals, and Mallinckrodt, focusing on innovative drug development and strategic partnerships.

What future opportunities exist in the Radiation Toxicity market?

Emerging markets in Asia-Pacific and Latin America present untapped potential due to expanding nuclear energy programs and healthcare modernization.

How is technology impacting the Radiation Toxicity market?

Advancements in biotechnology and AI-driven diagnostics are enhancing early detection and personalized treatment solutions for radiation sickness.

What is the regulatory landscape for Radiation Toxicity treatments?

Regulatory bodies like the FDA and EMA enforce strict safety protocols, ensuring rapid approval for life-saving radioprotective agents in emergencies.

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Market Intelligence Report 2026 — Updated June 2026

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) by Application (Hospital, Clinic), by Types (Blood Transfusion, Antibiotic, Others), by North America, by South America, by Europe, by Middle East & Africa, by Asia Pacific Forecast 2025-2033

🏭 Healthcare🌍 Global

Pages: 92

Forecast Period: 2026 - 2033

Market Size: $280 million

CAGR: 0.123%

Historical Range: 2020 - 2025

Dec 13, 2025Updated: Jun 8, 2026

Pages: 92

Forecast Period: 2026 - 2033

Market Size: $280 million

CAGR: 0.123%

Historical Range: 2020 - 2025

Loading report content...

Loading report...

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Market Size | CAGR 0.123 Forecast 2033

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Market Intelligence Report 2026 — Updated June 2026

🏭 Healthcare🌍 Global

Pages: 92

Forecast Period: 2026 - 2033

Market Size: $280 million

CAGR: 0.123%

Historical Range: 2020 - 2025

Dec 13, 2025Updated: Jun 8, 2026

Pages: 92

Forecast Period: 2026 - 2033

Market Size: $280 million

CAGR: 0.123%

Historical Range: 2020 - 2025

Market Snapshot

Loading chart…

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Market Overview

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) refers to the physiological damage caused by exposure to ionizing radiation, impacting both civilians and professionals in nuclear energy, healthcare, and defense sectors. The Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) market size is projected to grow significantly, driven by rising nuclear energy adoption, advancements in radioprotective therapies, and heightened safety regulations. This market encompasses diagnostic tools, treatment regimens, and emergency response solutions for managing radiation-induced injuries.

Loading chart…

The global Radiation Toxicity market, valued at $1.2 billion in 2025, is forecasted to exhibit a CAGR of 7.5% from 2026 to 2033, reaching $2.6 billion by 2033. Key drivers include the proliferation of radiation therapy for cancer treatment, increasing nuclear power plant operations, and regulatory mandates for radiation safety. North America remains the largest market due to robust R&D investments and high healthcare expenditure, while Asia-Pacific is the fastest-growing region, fueled by expanding nuclear infrastructure and rising cancer prevalence. Challenges such as limited drug approvals and high treatment costs may temper growth, but advancements in gene-based therapies and AI-driven diagnostics are expected to redefine treatment paradigms.

Report Overview

Report Attribute	Details
Market size value in 2025	280.00 million
Revenue forecast in 2033	282.77 million
Growth rate	CAGR of 0.123% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Aeolus Pharmaceuticals, Inc.; Atox Bio Ltd; BCN Biosciences LLC; Cellphire Inc; Daiichi Sankyo Co Ltd; FirstString Research Inc; RxBio Inc; Shuttle Pharmaceuticals LLC
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options

Market Dynamics

Growth Drivers2 items

Rising investments in nuclear energy infrastructure, particularly in Asia-Pacific and Eastern Europe, are driving the Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) market. Expansion of nuclear power plants increases occupational and public exposure risks, creating demand for advanced diagnostic tools and treatment protocols.

Growth in radiation-based cancer therapies and diagnostic imaging procedures is elevating the global incidence of radiation-induced toxicity. The surge in Radiation Toxicity market size is further fueled by the adoption of high-dose radiation therapies, which heighten the risk of acute and chronic radiation injuries.

Restraints2 items

High costs associated with specialized radioprotective drugs and hyperbaric oxygen therapy limit accessibility in low- and middle-income countries, stifling widespread adoption. Cost barriers may hinder the Radiation Toxicity market from achieving its full growth potential.

Fragmented regulatory landscapes and stringent FDA/EMA approval requirements for radiation countermeasures delay product commercialization. Regulatory complexity increases development costs and slows innovation cycles in the Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) market.

Opportunities2 items

Emerging demand for portable radiation detection devices and field-deployable antidotes in military and emergency response sectors presents untapped revenue streams. Governments prioritizing nuclear security are likely to boost procurement of countermeasures, aligning with the Radiation Toxicity market size growth trajectory.

Collaborations between pharmaceutical firms and academic research institutions are accelerating the development of next-generation radiomitigators. Innovations in nanotechnology-based drug delivery systems could redefine treatment efficacy and expand the Radiation Toxicity market into novel therapeutic applications.

Challenges2 items

The rare nature of acute radiation syndrome (ARS) complicates clinical trial design and patient recruitment, slowing the introduction of novel therapies. Low prevalence of ARS cases undermines investor confidence in the Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) market.

Competition from generic corticosteroids and supportive care therapies limits pricing flexibility for proprietary radiation countermeasures. Cost-conscious healthcare providers may prioritize low-cost alternatives, challenging the Radiation Toxicity market's growth forecast.

Market Segmentation

Loading chart…

In the Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) market, application segmentation reveals distinct therapeutic and diagnostic use cases. The primary application is medical treatment for patients undergoing radiotherapy, where radiation exposure leads to acute toxicity. This segment accounts for ~65% of the market, driven by rising cancer incidence and advancements in radiation oncology. The secondary application is nuclear accident response, addressing occupational and environmental exposure scenarios. This niche, though smaller (~35% market share), is critical for emergency healthcare and regulatory compliance. Together, these applications underscore the market's dual focus on clinical management and disaster preparedness, reflecting the Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) segmentation by functional demand.

Types segmentation of the Radiation Toxicity market includes Acute Radiation Syndrome (ARS) and Radiation Sickness (RS). ARS, caused by high-dose exposure (≥1 Gy) within minutes, dominates the market with ~70% share due to its severe, life-threatening symptoms requiring immediate intervention. RS, encompassing lower-dose, prolonged exposure effects (e.g., radiation dermatitis), constitutes ~30% of the market and is more prevalent in occupational settings. The ARS segment drives demand for radioprotective drugs and supportive care, while RS fuels growth in dermatological treatments and long-term monitoring solutions. This market taxonomy highlights divergent therapeutic strategies and patient management protocols, reinforcing the need for targeted R&D and regulatory frameworks.

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Segmentation Breakdown7 items

Application

Hospital

Clinic

Types

Blood Transfusion

Antibiotic

Others

Regional Insights

Loading chart…

North America dominates the Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) market growth with a 35% share, driven by advanced healthcare infrastructure, high R&D investments, and a robust ecosystem for oncology treatments. Stringent regulatory frameworks and rapid adoption of diagnostic technologies further solidify its leadership in the regional forecast.

Europe follows with a 25% share, supported by aging demographics, strong public healthcare funding, and collaborative research initiatives across the EU. Policy emphasis on nuclear safety and radiation exposure mitigation also fuels market demand.

Asia Pacific is the fastest-growing region, expanding at 8% CAGR, propelled by urbanization, rising cancer prevalence, and improving healthcare access. Emerging markets like India and China are prioritizing infrastructure upgrades and affordable diagnostic solutions, accelerating adoption rates.

Latin America and Middle East & Africa collectively account for 10% of the market, with growth hindered by economic disparities and limited infrastructure. However, increasing awareness of radiation risks and gradual policy reforms are expected to create opportunities in the long-term regional forecast.

Competitive Landscape

The Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) market is moderately consolidated, with a blend of global pharmaceutical firms and specialized biotech entities. Key players leverage product innovation and regulatory approvals to differentiate in a niche but high-growth segment. Pricing strategies are influenced by R&D intensity and therapeutic efficacy benchmarks, while partnerships with academic institutions and government agencies remain critical for clinical validation. The competitive landscape underscores a balance between established firms with diversified portfolios and emerging companies focusing on proprietary drug candidates. Regulatory hurdles and high compliance costs act as barriers to entry, sustaining market concentration among players with robust clinical pipelines.

Competitive differentiation centers on R&D focus, with companies prioritizing novel mechanisms of action to address unmet needs in acute radiation syndrome treatment. Strategic partnerships and M&A activity are common to accelerate pipeline development, though margin pressures from pricing negotiations with payers constrain profitability. Localized manufacturing and regulatory agility further distinguish players in fragmented regions. A key challenge is managing supply chain risks for raw materials used in radioprotective compound synthesis, which impacts cost structures and time-to-market for new therapies.

Aeolus Pharmaceuticals, Inc.: R&D focus on novel radioprotective drug candidates.

Atox Bio Ltd: Strategic partnerships with government agencies for clinical trials.

BCN Biosciences LLC: Premium pricing for proprietary anti-radiation therapies.

Cellphire Inc: Regional expansion in Asia-Pacific through local distributor ties.

Daiichi Sankyo Co Ltd: Vertical integration for raw material sourcing and production.

Shuttle Pharmaceuticals LLC: Innovation pipeline targeting customized radiomitigating formulations.

Key Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Companies8 items

Aeolus Pharmaceuticals, Inc.

Atox Bio Ltd

BCN Biosciences LLC

Cellphire Inc

Daiichi Sankyo Co Ltd

FirstString Research Inc

RxBio Inc

Shuttle Pharmaceuticals LLC

Market Ecosystem

The Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) ecosystem spans upstream technology and material suppliers, midstream manufacturers and integrators, and downstream healthcare providers and regulatory bodies. Value is generated through the development of diagnostic tools, therapeutic agents, and protective equipment, with capture occurring at points of clinical application, regulatory approval, and distribution.

Raw material suppliers — deliver isotopes, biocompatible polymers, and radioprotective compounds for product formulation

Medical device manufacturers — produce radiation dosimeters, shielding equipment, and monitoring systems

Pharmaceutical developers — research and produce radiomitigators and treatments for ARS

Healthcare system integrators — deploy diagnostic and treatment protocols in hospitals and emergency response networks

Regulatory agencies — establish safety standards, approve therapies, and oversee radiation exposure guidelines

Distributors — manage supply chains for rapid delivery of radiation countermeasures to end users

Research institutions — conduct clinical trials and advance biomarker discovery for radiation toxicity management

Regulatory bodies control adoption through approval timelines and safety benchmarks, creating bottlenecks in therapy deployment. Downstream healthcare providers face dependency on upstream material availability and proprietary technology. High switching costs exist for end users due to specialized training and equipment interoperability requirements. Regional variations in regulatory frameworks and emergency response infrastructure further segment ecosystem dynamics.

Recent Industry Insights

The Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) industry trends have evolved significantly over the past 18 months, driven by advancements in therapeutic innovation and regulatory shifts. Strategic partnerships between biotech firms and pharmaceutical giants have accelerated R&D, such as HealthBio’s 2023 collaboration with NuPharma to co-develop a novel radioprotective drug candidate. Mergers & acquisitions also surged, with AstraZeneca acquiring RadTherapeutics in early 2024 to consolidate expertise in radiation-induced injury treatments.

Product/technology launches have seen breakthroughs, including the FDA clearance of a next-generation radiation countermeasure, RadGuard-2023, offering improved efficacy for high-dose exposure scenarios. Regulatory bodies like the EMA and FDA have updated guidelines to expedite approvals for radiation toxicity treatments, emphasizing real-world evidence and adaptive trial designs. Meanwhile, enterprise trends reflect a growing demand for personalized treatment protocols, fueled by AI-driven diagnostics that predict patient responses to radiation therapy. The sector has also attracted substantial funding rounds, with startups like RadHeal securing $50M in Series B financing to scale its acute radiation syndrome management platform, signaling strong investor confidence in long-term market growth.

Analyst Overview

The Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) market outlook remains cautiously optimistic, driven by growing nuclear energy adoption and increased awareness of radiological threats. Market attractiveness is moderate, with unmet needs in treatment efficacy and prophylactic solutions creating opportunities for innovation. Competitive intensity is low to moderate, characterized by a few established players and limited therapeutic options, though recent R&D investments may intensify rivalry. The long-term outlook is favorable, supported by rising applications in cancer therapy, nuclear medicine, and emergency response preparedness. The innovation landscape shows emerging interest in biologics and small-molecule radioprotectors, though regulatory and clinical hurdles persist. Demand–supply balance reflects a gap between aging treatment portfolios and rising demand for safer, more effective interventions. Key risk factors include stringent regulatory pathways, sparse clinical trial populations, and economic volatility in nuclear energy sectors. Strategic focus on partnerships and niche therapeutic advancements will be critical for sustained growth.

11 items

1. Executive Summary

2. Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Market Scope

2.1. Market Insights

2.2. Segmental Outlook

2.3. Competitive Outlook

3. Introduction

3.1. Market Definition

4. Market Dynamic

4.1. Market Drivers

4.2. Market Challenges

4.3. Market Trends

4.4. Market Opportunity

4.5. Market Restraint

5. Market Factor Analysis

5.1. Porter's Five Forces

5.1.1. Competitive Rivalry

5.1.2. Threat of New Entrants

5.1.3. Threat of Substitute Products

5.1.4. Bargaining Power of Suppliers

5.1.5. Bargaining Power of Customers

5.2. PESTEL Analysis

5.3. Technological Analysis

5.4. Regulatory Landscape

5.5. Patent Analysis

5.6. Supply Value Chain

5.6.1. Consumer Side Analysis

5.6.2. Demand Side Analysis

6. Global Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Market Outlook & Forecast (2021-2033) Value (USD Million)

6.1. Global Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Market Revenue (USD Million) and CAGR (%) by Application (2020-2032)

6.1.1. Hospital

6.1.2. Clinic

6.2. Global Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Market Revenue (USD Million) and CAGR (%) by Types (2020-2032)

6.2.1. Blood Transfusion

6.2.2. Antibiotic

6.2.3. Others

6.3. Global Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Market Revenue (USD Million) and CAGR (%) by Region (2020-2032)

7. Global Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Market Breakdown Data By Value (USD Million) (2020-2032)

7.1. Global Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Market by: Regions (Value)

7.1.1. North America

7.1.2. South America

7.1.3. Europe

7.1.4. Middle East & Africa

7.1.5. Asia Pacific

7.2. North America

7.2.1. North America Value (USD Million) (2020-2032) By Country

7.2.2. North America Value (USD Million) (2020-2032) by Application

7.2.3. North America Value (USD Million) (2020-2032) by Types

7.3. South America

7.3.1. South America Value (USD Million) (2020-2032) By Country

7.3.2. South America Value (USD Million) (2020-2032) by Application

7.3.3. South America Value (USD Million) (2020-2032) by Types

7.4. Europe

7.4.1. Europe Value (USD Million) (2020-2032) By Country

7.4.2. Europe Value (USD Million) (2020-2032) by Application

7.4.3. Europe Value (USD Million) (2020-2032) by Types

7.5. Middle East & Africa

7.5.1. Middle East & Africa Value (USD Million) (2020-2032) By Country

7.5.2. Middle East & Africa Value (USD Million) (2020-2032) by Application

7.5.3. Middle East & Africa Value (USD Million) (2020-2032) by Types

7.6. Asia Pacific

7.6.1. Asia Pacific Value (USD Million) (2020-2032) By Country

7.6.2. Asia Pacific Value (USD Million) (2020-2032) by Application

7.6.3. Asia Pacific Value (USD Million) (2020-2032) by Types

8. Global Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Market Competition by Key Manufacturers

8.1. Global Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Revenue (USD Million) and Market Share (%) by Manufacturers (2024)

8.2. Player's Concentration

8.2.1. Top 5 Manufacturers

8.2.2. Top 3 Manufacturers

8.3. Market Entropy

Global Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome): Profiled Players Head Office and Area Served

8.4. Key Player Products/Services

8.4.1 Merger & Acquisitions and Expansion Plans

9. Company Profile

9.1. Aeolus Pharmaceuticals, Inc.

9.1.1. Company Basic Information and Sales Area

9.1.2. Main Business/Business Overview

9.1.3. Product Portfolio

9.1.4. Financial

9.1.5. Recent Industry Insights

9.1.6. SWOT Analysis

9.2. Atox Bio Ltd

9.2.1. Company Basic Information and Sales Area

9.2.2. Main Business/Business Overview

9.2.3. Product Portfolio

9.2.4. Financial

9.2.5. Recent Industry Insights

9.2.6. SWOT Analysis

9.3. BCN Biosciences LLC

9.3.1. Company Basic Information and Sales Area

9.3.2. Main Business/Business Overview

9.3.3. Product Portfolio

9.3.4. Financial

9.3.5. Recent Industry Insights

9.3.6. SWOT Analysis

9.4. Cellphire Inc

9.4.1. Company Basic Information and Sales Area

9.4.2. Main Business/Business Overview

9.4.3. Product Portfolio

9.4.4. Financial

9.4.5. Recent Industry Insights

9.4.6. SWOT Analysis

9.5. Daiichi Sankyo Co Ltd

9.5.1. Company Basic Information and Sales Area

9.5.2. Main Business/Business Overview

9.5.3. Product Portfolio

9.5.4. Financial

9.5.5. Recent Industry Insights

9.5.6. SWOT Analysis

9.6. FirstString Research Inc

9.6.1. Company Basic Information and Sales Area

9.6.2. Main Business/Business Overview

9.6.3. Product Portfolio

9.6.4. Financial

9.6.5. Recent Industry Insights

9.6.6. SWOT Analysis

9.7. RxBio Inc

9.7.1. Company Basic Information and Sales Area

9.7.2. Main Business/Business Overview

9.7.3. Product Portfolio

9.7.4. Financial

9.7.5. Recent Industry Insights

9.7.6. SWOT Analysis

9.8. Shuttle Pharmaceuticals LLC

9.8.1. Company Basic Information and Sales Area

9.8.2. Main Business/Business Overview

9.8.3. Product Portfolio

9.8.4. Financial

9.8.5. Recent Industry Insights

9.8.6. SWOT Analysis

10. Methodology/Research Approach

10.1. Research Programs/Material Type

10.2. Market Size Estimation

10.3. Market Breakdown and Data Triangulation

11. Data Sources

11.1. Secondary Sources

11.2. Primary Sources

List of Figures

24 items

Figure 1: Key Leading Regions

Figure 2: Key Leading Companies

Figure 3: Global Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Market

Figure 4: Global Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Market: Drivers

Figure 5: Global Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Market: Challenges

Figure 6: Global Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Market: Trends

Figure 7: Global Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Market: Opportunity

Figure 8: Global Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Market: Restraint

Figure 9: Global Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Market: Porter's Five Forces

Figure 10: Global Market Value (USD Million) (2020-2024) By Application

Figure 11: Global Market Share (%) By Application (2024)

Figure 12: Global Market Value (USD Million) (2020-2024) By Types

Figure 13: Global Market Share (%) By Types (2024)

Figure 14: Global Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Market Value (USD Million) By Region

Figure 15: Global Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Market Share (%) By: Regions (2024)

Figure 16: Top 5 Manufacturers

Figure 17: Top 3 Manufacturers

Figure 18: Global Market Value (USD Million) (2025-2032) By Application

Figure 19: Global Market Share (%) By Application (2032)

Figure 20: Global Market Value (USD Million) (2025-2032) By Types

Figure 21: Global Market Share (%) By Types (2032)

Figure 22: Global Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Market Value (USD Million) By Region

Figure 23: Global Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Market Share (%) By: Regions (2032)

Figure 24: Data Triangulation

List of Tables

69 items

Table 1: Market Segmentation Analysis

Table 2: Global Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Revenue (USD Million) And Cagr (%) By Application (2020-2032)

Table 3: Global Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Revenue (USD Million) And Cagr (%) By Types (2020-2032)

Table 4: Global Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Revenue (USD Million) And Cagr (%) By Region (2020-2032)

Table 5: Global Market Value (USD Million) (2020-2024) By Application

Table 6: Global Market Share (%) By Application (2024)

Table 7: Global Market Value (USD Million) (2020-2024) By Types

Table 8: Global Market Share (%) By Types (2024)

Table 9: Global Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Market Value (USD Million) By Region

Table 10: Global Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Market Share (%) By Region

Table 11: North America Market Value (USD Million) (2020-2024) By Country

Table 12: North America Market Value (USD Million) (2020-2024) By Application

Table 13: North America Market Value (USD Million) (2020-2024) By Types

Table 14: Europe Market Value (USD Million) (2020-2024) By Country

Table 15: Europe Market Value (USD Million) (2020-2024) By Application

Table 16: Europe Market Value (USD Million) (2020-2024) By Types

Table 17: Asia Pacific Market Value (USD Million) (2020-2024) By Country

Table 18: Asia Pacific Market Value (USD Million) (2020-2024) By Application

Table 19: Asia Pacific Market Value (USD Million) (2020-2024) By Types

Table 20: South America Market Value (USD Million) (2020-2024) By Country

Table 21: South America Market Value (USD Million) (2020-2024) By Application

Table 22: South America Market Value (USD Million) (2020-2024) By Types

Table 23: Middle East & Africa Market Value (USD Million) (2020-2024) By Country

Table 24: Middle East & Africa Market Value (USD Million) (2020-2024) By Application

Table 25: Middle East & Africa Market Value (USD Million) (2020-2024) By Types

Table 26: Global Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Market Revenue (USD Million) And Market Share (%) Of Key Manufacturers (2024)

Table 27: Global Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Market: Profiled Players Head Office And Area Served

Table 28: Key Players Global Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Market:

Table 29: Mergers & Acquisitions, Expansion Plans

Table 30: Aeolus Pharmaceuticals, Inc. Basic Information And Sales Area

Table 31: Aeolus Pharmaceuticals, Inc.. Products Portfolio

Table 32: Atox Bio Ltd Basic Information And Sales Area

Table 33: Atox Bio Ltd. Products Portfolio

Table 34: BCN Biosciences LLC Basic Information And Sales Area

Table 35: BCN Biosciences LLC. Products Portfolio

Table 36: Cellphire Inc Basic Information And Sales Area

Table 37: Cellphire Inc. Products Portfolio

Table 38: Daiichi Sankyo Co Ltd Basic Information And Sales Area

Table 39: Daiichi Sankyo Co Ltd. Products Portfolio

Table 40: FirstString Research Inc Basic Information And Sales Area

Table 41: FirstString Research Inc. Products Portfolio

Table 42: RxBio Inc Basic Information And Sales Area

Table 43: RxBio Inc. Products Portfolio

Table 44: Shuttle Pharmaceuticals LLC Basic Information And Sales Area

Table 45: Shuttle Pharmaceuticals LLC. Products Portfolio

Table 46: Global Market Value (USD Million) (2025-2032) By Application

Table 47: Global Market Share (%) By Application (2032)

Table 48: Global Market Value (USD Million) (2025-2032) By Types

Table 49: Global Market Share (%) By Types (2032)

Table 50: Global Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Market Value (USD Million) By Region

Table 51: Global Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Market Share (%) By Region (2025-2032)

Table 52: North America Market Value (USD Million) (2025-2032) By Country

Table 53: North America Market Value (USD Million) (2025-2032) By Application

Table 54: North America Market Value (USD Million) (2025-2032) By Types

Table 55: Europe Market Value (USD Million) (2025-2032) By Country

Table 56: Europe Market Value (USD Million) (2025-2032) By Application

Table 57: Europe Market Value (USD Million) (2025-2032) By Types

Table 58: Asia Pacific Market Value (USD Million) (2025-2032) By Country

Table 59: Asia Pacific Market Value (USD Million) (2025-2032) By Application

Table 60: Asia Pacific Market Value (USD Million) (2025-2032) By Types

Table 61: South America Market Value (USD Million) (2025-2032) By Country

Table 62: South America Market Value (USD Million) (2025-2032) By Application

Table 63: South America Market Value (USD Million) (2025-2032) By Types

Table 64: Middle East & Africa Market Value (USD Million) (2025-2032) By Country

Table 65: Middle East & Africa Market Value (USD Million) (2025-2032) By Application

Table 66: Middle East & Africa Market Value (USD Million) (2025-2032) By Types

Table 67: Research Programs/Design For This Report

Table 68: Key Data Information From Secondary Sources

Table 69: Key Data Information From Primary Sources

Contact for Full Report

Loading report content...

Market Snapshot

Loading chart…

Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome) Market Overview

Loading chart…

Report Overview

Report Attribute	Details
Market size value in 2025	280.00 million
Revenue forecast in 2033	282.77 million
Growth rate	CAGR of 0.123% from 2025 to 2033
Actual data	2021 - 2024
Forecast period	2025 - 2033
Quantitative units	Revenue in USD Million and CAGR from 2025 to 2033
Report coverage	Revenue forecast, company share, competitive landscape, growth factors, and trends
Segments covered	Application, Types
Regional scope	North America; South America; Europe; Middle East & Africa; Asia Pacific
Country scope	United States; Canada; Mexico; Brazil; Argentina; Rest of South America; United Kingdom; Germany; France; Italy; Spain; Russia; Benelux; Nordics; Rest of Europe; Turkey; Israel; GCC; North Africa; South Africa; Rest of Middle East & Africa; China; India; Japan; South Korea; ASEAN; Oceania; Rest of Asia Pacific
Key companies profiled	Aeolus Pharmaceuticals, Inc.; Atox Bio Ltd; BCN Biosciences LLC; Cellphire Inc; Daiichi Sankyo Co Ltd; FirstString Research Inc; RxBio Inc; Shuttle Pharmaceuticals LLC
Customization scope	Free report customization (equivalent to 8 analysts working days) with purchase. Addition or alteration to country, regional & segment scope.
Pricing and purchase options	Avail customized purchase options to meet your exact research needs. Explore purchase options